ArticleHuman vaccines & immunotherapeutics2021
SARS‑CoV-2 RBD219-N1C1: A yeast-expressed SARS-CoV-2 recombinant receptor-binding domain candidate vaccine stimulates virus neutralizing antibodies and T-cell immunity in mice.
Open access · greenAbstract read
In one paragraph
Article in Human vaccines & immunotherapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.
0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed
5.9field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 100 citations in OpenAlex.
- Immunogenicity and safety of Biological E's CORBEVAX™ vaccine compared to COVISHIELD™ (ChAdOx1 nCoV-19) vaccine studied in a phase-3, single blind, multicentre, randomized clinical trial.Human vaccines & immunotherapeutics · 2023Trial
- Yeast-Based Vaccine Platforms: Applications and Key Insights from the COVID-19 Era.Biomolecules · 2026Review
- A Brief History of the Pichia pastoris Expression System.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Safety and immunogenicity of booster doses of an XBB.1.5 RBD subunit COVID-19 vaccine among individuals aged 5-80 years in India: a phase 3, single-blind, randomised controlled trial.The Lancet regional health. Southeast Asia · 2025Article
- Development of a self-assembling multimeric Bann-RBD fusion protein in Pichia pastoris as a potential COVID-19 vaccine candidate.Scientific reports · 2025Article
- Yeast vaccine production platform for human and animal infectious diseases.Frontiers in immunology · 2025Review
- Heterologous prime-pull mucosal vaccination with an adjuvanted RBD vaccine elicits robust IgA production and protects against SARS-CoV-2.Frontiers in immunology · 2025Article
- Review
- Backstage Heroes-Yeast in COVID-19 Research.International journal of molecular sciences · 2024Review
- Optimization of Cellular Transduction by the HIV-Based Pseudovirus Platform with Pan-Coronavirus Spike Proteins.Viruses · 2024Article
- Protective RBD-dimer vaccines against SARS-CoV-2 and its variants produced in glycoengineered Pichia pastoris.PLoS pathogens · 2024Article
- Vaccine Science Diplomacy and "The Phenomenon of Man".The Linacre quarterly · 2024Article
- A trivalent protein-based pan-Betacoronavirus vaccine elicits cross-neutralizing antibodies against a panel of coronavirus pseudoviruses.NPJ vaccines · 2024Article
- A Journey in Science: Molecular vaccines for global child health in troubled times of anti-science.Molecular medicine (Cambridge, Mass.) · 2024Article
- Production and Immunogenicity Assessment of LTp50: AnPharmaceuticals (Basel, Switzerland) · 2024Article
- Unlocking Nature's Toolbox: glutamate-inducible recombinant protein production from the Komagatella phaffii PEPCK promoter.Microbial cell factories · 2024Article
- Review
- Structure-based design of oligomeric receptor-binding domain (RBD) recombinant proteins as potent vaccine candidates against SARS-CoV-2.Human vaccines & immunotherapeutics · 2023Article
- A trimeric spike-based COVID-19 vaccine candidate induces broad neutralization against SARS-CoV-2 variants.Human vaccines & immunotherapeutics · 2023Article
- Article
Corrections and comments
- Update of
Authors and funding
20 authors at 3 institutions in 1 country.
Jeroen PolletTexas Children's Hospital Center for Vaccine Development, Houston, TX, USA.ORCID 0000-0003-1420-4015
Wen-Hsiang ChenTexas Children's Hospital Center for Vaccine Development, Houston, TX, USA.
Leroy VersteegTexas Children's Hospital Center for Vaccine Development, Houston, TX, USA.
Brian KeeganTexas Children's Hospital Center for Vaccine Development, Houston, TX, USA.
Bin ZhanTexas Children's Hospital Center for Vaccine Development, Houston, TX, USA.
Junfei WeiTexas Children's Hospital Center for Vaccine Development, Houston, TX, USA.
Zhuyun LiuTexas Children's Hospital Center for Vaccine Development, Houston, TX, USA.
Jungsoon LeeTexas Children's Hospital Center for Vaccine Development, Houston, TX, USA.
Rahki KunduTexas Children's Hospital Center for Vaccine Development, Houston, TX, USA.
Rakesh AdhikariTexas Children's Hospital Center for Vaccine Development, Houston, TX, USA.
Cristina PovedaTexas Children's Hospital Center for Vaccine Development, Houston, TX, USA.
Maria Jose VillarTexas Children's Hospital Center for Vaccine Development, Houston, TX, USA.
Ana Carolina de Araujo LeaoTexas Children's Hospital Center for Vaccine Development, Houston, TX, USA.
Joanne Altieri RiveraTexas Children's Hospital Center for Vaccine Development, Houston, TX, USA.
Zoha MominDepartment of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, USA.
Portia M GillespieTexas Children's Hospital Center for Vaccine Development, Houston, TX, USA.ORCID 0000-0003-2951-4550
Jason T KimataDepartment of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, USA.
Ulrich StrychTexas Children's Hospital Center for Vaccine Development, Houston, TX, USA.
Peter J HotezTexas Children's Hospital Center for Vaccine Development, Houston, TX, USA.ORCID 0000-0001-8770-1042
Maria Elena BottazziTexas Children's Hospital Center for Vaccine Development, Houston, TX, USA.
Texas Children's Hospital · USBaylor College of Medicine · USBaylor University · US
Funding
Tumor BiologyP30CA125123 · NCI · BAYLOR COLLEGE OF MEDICINE · PI DAVID R ROWLEY · 2007 to 2026
$73.9MTexas Developmental Center for AIDS ResearchP30AI161943 · NIAID · BAYLOR COLLEGE OF MEDICINE · PI GIORDANO, THOMAS P · 2021 to 2025
$8.3MDevelopment of a safe and effective RBD-based vaccine against MERS-CoVR56AI140872 · NIAID · BAYLOR COLLEGE OF MEDICINE · PI HOTEZ, PETER J · 2020 to 2020
$549kBD Biosciences Special Order LSRIIS10RR024574 · NCRR · BAYLOR COLLEGE OF MEDICINE · PI LUMPKIN, ELLEN A · 2009 to 2009
$430kNCI NIH HHS P30 CA125123NCRR NIH HHS S10 RR024574NIAID NIH HHS P30 AI161943NIAID NIH HHS R56 AI140872
Abstract
There is an urgent need for an accessible and low-cost COVID-19 vaccine suitable for low- and middle-income countries. Here, we report on the development of a SARS-CoV-2 receptor-binding domain (RBD) protein, expressed at high levels in yeast (
Indexed as
COVID-19Spike Glycoprotein, CoronavirusAnimalsAntibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesHumansMiceMice, Inbred BALB CProtein DomainsSaccharomyces cerevisiaeSaccharomycetalesSARS-CoV-2T-LymphocytesAntibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesSpike Glycoprotein, CoronavirusACE-2alumcoronavirusCOVID-19pseudovirusRBD
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.